Christopher O Barnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8499925/publications.pdf Version: 2024-02-01

		394421	642732
23	9,271	19	23
papers	citations	h-index	g-index
35	35	35	14983
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	27.8	1,742
2	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	27.8	1,355
3	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687.	27.8	1,346
4	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	27.8	1,232
5	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	28.9	724
6	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	27.8	610
7	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	12.8	332
8	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science, 2021, 371, 735-741.	12.6	305
9	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	14.3	230
10	De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science, 2020, 370, 1208-1214.	12.6	172
11	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	27.8	145
12	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	27.8	108
13	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	28.9	106
14	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host and Microbe, 2018, 24, 579-592.e4.	11.0	88
15	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nature Communications, 2018, 9, 1251.	12.8	85
16	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	14.3	85
17	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	6.4	80
18	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	28.9	73

#	Article	IF	CITATIONS
19	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 2021, 12, 4886.	12.8	65
20	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533.	12.4	27
21	Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation. Nature Communications, 2021, 12, 1950.	12.8	22
22	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. Cell Reports, 2022, 38, 110348.	6.4	14
23	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, .	6.0	10